Eleonora Baldonero

Eleonora Baldonero

Auto-generated profile, based on publicly available information

Eleonora Baldonero

Department of Geriatrics, Centre for the Medicine of the Ageing, Neurosciences and Orthopedics, Catholic University, Rome, Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2011 in Neurology
Verified
Journal Article
Closed access
PDF file
NCNicoletta Ciccarelli
Nicoletta Ciccarelli
Massimiliano FabbianiMassimiliano Fabbiani
Massimiliano Fabbiani
SGS. Di Giambenedetto
S. Di Giambenedetto
IFI. Fanti
I. Fanti
EBE. Baldonero
E. Baldonero
MSM.C. Silveri
M.C. Silveri
Background: Despite the availability of potent antiretroviral regimens (combination antiretroviral therapy [cART]), HIV-associated neurocognitive disorders (HAND) are increasingly recognized. Our aim was to investigate the prevalence and treatment-related correlates of HAND, exploring the potential neurotoxicity of antiretrovirals on cognitive functions. Methods: We performed a cross-sectional single cohort study by consecutively enrolling asymptomatic HIV+ subjects during routine outpatient visits. Each patient was submitted to a comprehensive neuropsychological battery and was considered cognitively impaired on the basis of results obtained in matched healthy HIV-negative subjects. CNS penetration effectiveness (CPE) rank was calculated for cART regimens according to 2010 CHARTER criteria. Factors associated with cognitive impairment were investigated by linear or logistic regression analysis. Results: A total of 146 patients were enrolled. Of these, 129 (88.4%) were on cART and 59.6% of them were on current regimen from ≥1 year. Sixty-nine patients (47%) were classified as cognitively impaired (35.6% asymptomatic and 11.6% mild neurocognitive impairment). In the multivariate analysis, efavirenz use (odds ratio [OR] = 4.00; p = 0.008) and non-Italian nationality (OR = 3.46; p = 0.035) were associated with increased risk of cognitive impairment, whereas higher education was associated with a lower risk (OR = 0.85; p = 0.002). Furthermore, efavirenz use and age ≥65 years independently predicted worse performance on the double barrage and the Stroop test (time). No association between CPE rank and cognitive impairment was observed. Conclusions: A high prevalence of HAND was observed in apparently asymptomatic HIV+ individuals. HAND was associated with efavirenz use, suggesting the potential neurotoxicity of this drug. Routine neuropsychological examinations could help clinicians make correct diagnoses and manage mild, but clinically relevant, forms of HAND.

21 September 2012 in HIV Medicine
Verified
Journal Article
Closed access
PDF file
Massimiliano FabbianiMassimiliano Fabbiani
Massimiliano Fabbiani
NCNicoletta Ciccarelli
Nicoletta Ciccarelli
MTM Tana
M Tana
SFS Farina
S Farina
EBE Baldonero
E Baldonero
SGS Di Giambenedetto
S Di Giambenedetto

1 July 2012 in Neuropsychologia
Verified
Journal Article
Closed access
MSMaria Caterina Silveri
Maria Caterina Silveri
NCNicoletta Ciccarelli
Nicoletta Ciccarelli
EBEleonora Baldonero
Eleonora Baldonero
CPCarla Piano
Carla Piano
MZMassimiliano Zinno
Massimiliano Zinno
ADAntonio Daniele
Antonio Daniele

18 November 2012 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
ABAnna Rita Bentivoglio
Anna Rita Bentivoglio
EBEleonora Baldonero
Eleonora Baldonero
LRLucia Ricciardi
Lucia Ricciardi
FNFrancesca De Nigris
Francesca De Nigris
ADAntonio Daniele
Antonio Daniele

10 July 2013 in Infection
Verified
Journal Article
Closed access
PDF file
NCNicoletta Ciccarelli
Nicoletta Ciccarelli
Massimiliano FabbianiMassimiliano Fabbiani
Massimiliano Fabbiani
PGP. Grima
P. Grima
KFK. Falasca
K. Falasca
MTM. Tana
M. Tana
SGS. Di Giambenedetto
S. Di Giambenedetto

1 May 2014 in Antiviral Therapy
Verified
Journal Article
Closed access
Massimiliano FabbianiMassimiliano Fabbiani
Massimiliano Fabbiani
PGPierfrancesco Grima
Pierfrancesco Grima
BMBenedetta Milanini
Benedetta Milanini
AMAnnalisa Mondi
Annalisa Mondi
EBEleonora Baldonero
Eleonora Baldonero
SGSimona Di Giambenedetto
Simona Di Giambenedetto
Background: The aim of the study was to explore how viral resistance and antiretroviral central nervous system (CNS) penetration could impact on cognitive performance of HIV-infected patients. Methods: We performed a multicentre cross-sectional study enrolling HIV-infected patients undergoing neuropsychological testing, with a previous genotypic resistance test on plasma samples. CNS penetration-effectiveness (CPE) scores and genotypic susceptibility scores (GSS) were calculated for each regimen. A composite score (CPE-GSS) was then constructed. Factors associated with cognitive impairment were investigated by logistic regression analysis. Results: A total of 215 patients were included. Mean CPE was 7.1 (95% CI 6.9, 7.3) with 206 (95.8%) patients showing a CPE≥6. GSS correction decreased the CPE value in 21.4% (mean 6.5, 95% CI 6.3, 6.7), 26.5% (mean 6.4, 95% CI 6.1, 6.6) and 24.2% (mean 6.4, 95% CI 6.2, 6.6) of subjects using ANRS, HIVDB and REGA rules, respectively. Overall, 66 (30.7%) patients were considered cognitively impaired. No significant association could be demonstrated between CPE and cognitive impairment. However, higher GSS-CPE was associated with a lower risk of cognitive impairment (CPE-GSS ANRS odds ratio 0.75, P=0.022; CPE-GSS HIVDB odds ratio 0.77, P=0.038; CPE-GSS REGA odds ratio 0.78, P=0.038). Overall, a cutoff of CPE-GSS≥5 seemed the most discriminatory according to each different interpretation system. Conclusions: GSS-corrected CPE score showed a better correlation with neurocognitive performance than the standard CPE score. These results suggest that antiretroviral drug susceptibility, besides drug CNS penetration, can play a role in the control of HIV-associated neurocognitive disorders.